Opinion|Videos|August 20, 2026
Real-World Experience and Integrating FLAURA2, TOP, and FLAME Into Practice
Author(s)Sandip Patel, MD, Amy Cummings, MD, PhD,
The faculty discuss how these data are applied in practice and where real-world experience sits in the evidence hierarchy.
Advertisement
The faculty discuss how these data are applied in practice and where real-world experience sits in the evidence hierarchy. Synthesizing FLAURA2, TOP, and FLAME, the faculty conclude that patients with high-risk disease based on the burden (i.e. brain metastases, painful bone metastases, high tumor shedding) or TP53 co-mutation should prompt intensification.
Advertisement
Related to this article
Tovecimig plus paclitaxel improved objective response over paclitaxel alone in previously treated advanced biliary tract cancer in COMPANION-002.
Adding LK101 to tislelizumab-based first-line maintenance yielded early antitumor activity and signs of immune activation in advanced NSCLC.
Adding durvalumab and enfortumab vedotin around cystectomy extended survival in muscle-invasive bladder cancer without cisplatin options.
Adding pembrolizumab to adjuvant radiation did not meet prespecified superiority criteria in patients with stage I/II high-intermediate–risk dMMR endometrioid endometrial cancer in the phase 3 NRG-GY020 trial.
Adding tarlatamab-dlle to durvalumab maintenance extended survival in extensive-stage small cell lung cancer in the phase 3 DeLLphi-305 trial.
Adding intismeran autogene to pembrolizumab cut the risk of recurrence and distant metastasis in resected high-risk melanoma in INTerpath-001.
Adding darolutamide to androgen deprivation and primary or salvage radiation lowered metastasis risk in very high-risk localized prostate cancer.
INCA33890 combined with standard-of-care therapy produced responses in first- and third-line metastatic microsatellite stable colorectal cancer.
Advertisement
Advertisement
Trending on OncLive
1
Durvalumab Plus Enfortumab Vedotin Improves Survival in Cisplatin-Ineligible MIBC
2
Adjuvant Intismeran Autogene Plus Pembrolizumab Improves RFS and DMFS in Melanoma
3
DASL-HiCaP: Darolutamide Plus ADT and Radiation Therapy Improves MFS in Very High-Risk Localized Prostate Cancer
4
DeLLphi-305 Data Support Frontline Maintenance Tarlatamab Plus Durvalumab as a New SOC in ES-SCLC
5